ARCHITECT
Device
Abbott Laboratories
Total Payments
$10.3M
Transactions
512
Doctors
161
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $7.3M | 107 | 58 |
| 2023 | $2.2M | 156 | 55 |
| 2022 | $818,622 | 226 | 40 |
| 2017 | $35,260 | 23 | 19 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8.6M | 111 | 83.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $790,754 | 58 | 7.7% |
| Consulting Fee | $731,150 | 34 | 7.1% |
| Debt forgiveness | $128,154 | 97 | 1.2% |
| Travel and Lodging | $29,040 | 60 | 0.3% |
| Long term medical supply or device loan | $8,696 | 5 | 0.1% |
| Food and Beverage | $6,109 | 147 | 0.1% |
Payments by Type
Research
$8.6M
111 transactions
General
$1.7M
401 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| TBI Adult Training Study (CLIN 0001) | Abbott Laboratories | $3.8M | 0 |
| TBI Pediatric Feasibility Study (CLIN 00 | Abbott Laboratories | $2.0M | 0 |
| Complete analysis of host response profiling of serum and whole blood from MPXV patients by transcri | Abbott Laboratories | $377,778 | 0 |
| Evaluation of Cardiovascular Biomarkers in the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (Fourier TIMI 59) | Abbott Laboratories | $285,158 | 0 |
| Institution will provide samples from approximately 750 patients from the PROVE-HF study and from the ICON-RELOADED study | Abbott Laboratories | $250,000 | 0 |
| Community Collaboration to Combat Coronavirus (C4WARD) Study | Abbott Laboratories | $217,903 | 0 |
| Longitudinal Electronic Medical Record Data Access | Abbott Laboratories | $200,000 | 0 |
| Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL): Biomarker Sub-study | Abbott Laboratories | $180,809 | 0 |
| Understanding the Role of Novel HBV Assays to Improve the Characterization of Acute and Chronic Hepa | Abbott Laboratories | $149,896 | 0 |
| Transforming Research and Clinical Knowledge in Traumatic Brain Injury | Abbott Laboratories | $120,000 | 0 |
| COVID REGISTRY DATA ACCESS | Abbott Laboratories | $110,000 | 0 |
| Viral Surveillance and Discovery in the US | Abbott Laboratories | $100,000 | 0 |
| (SARCOMA) Biomarkers of cardiotoxicity in anthracycline treated SARCOMA | Abbott Laboratories | $76,439 | 0 |
| Association of Galectin-3 and High Sensitive Troponin-I Level | Abbott Laboratories | $75,943 | 0 |
| Troponin Autoantibodies in Patients with Immune Checkpoint Inhibitor Myocarditis | Abbott Laboratories | $56,374 | 0 |
| CMR Detection of Myocardial Damage from COVID-19 | Abbott Laboratories | $51,583 | 0 |
| Performance of high sensitivity troponin in patients with acute chest pain presenting to the emergency department | Abbott Laboratories | $50,094 | 0 |
| Test well-characterized specimens and controls from pediatric patients with different disease states provided by the Boston Childrens Hospital | Abbott Laboratories | $45,000 | 0 |
| Panel/algorithm development for prediction of aggressive vs. indolent prostate cancer. | Abbott Laboratories | $40,000 | 0 |
| SpecimenCollectionfortheEvaluationofAlereNT-proBNPforAlinityiSysteminan Emergency Department Setting for Heart Failure (LANER-HF) | Abbott Laboratories | $37,422 | 0 |
Top Doctors Receiving Payments for ARCHITECT — Page 7
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , CRNA | Nurse Anesthetist, Certified Registered | Philadelphia, PA | $15.52 | 1 |
| , MD | Anatomic Pathology & Clinical Pathology | East Norriton, PA | $15.52 | 1 |
| Paul Belser | — | East Norriton, PA | $15.52 | 1 |
| , MD | Internal Medicine | Oakdale, CA | $15.34 | 1 |
| , M.D., PH.D | Blood Banking & Transfusion Medicine | Westbury, NY | $15.31 | 1 |
| , MD | Cardiovascular Disease | Little Rock, AR | $14.27 | 1 |
| , PA | Emergency Medicine | Los Angeles, CA | $13.14 | 1 |
| , MD | Pain Medicine | Eugene, OR | $10.72 | 1 |
| , M.D | Cardiovascular Disease | Rochester, MN | $9.67 | 1 |
| , MD | Cardiovascular Disease | Boston, MA | $9.67 | 1 |
| , MD | Internal Medicine | Johnstown, PA | $7.23 | 1 |
| , MD | Internal Medicine | Bastrop, TX | $5.48 | 1 |
Ad
Manufacturing Companies
- Abbott Laboratories $10.3M
- GE HEALTHCARE $35,260
Product Information
- Type Device
- Total Payments $10.3M
- Total Doctors 161
- Transactions 512
About ARCHITECT
ARCHITECT is a device associated with $10.3M in payments to 161 healthcare providers, recorded across 512 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.
Payment data is available from 2017 to 2024. In 2024, $7.3M was paid across 107 transactions to 58 doctors.
The most common payment nature for ARCHITECT is "Unspecified" ($8.6M, 83.6% of total).
ARCHITECT is associated with 20 research studies, including "TBI Adult Training Study (CLIN 0001)" ($3.8M).